Analysts Set Avantor, Inc. (NYSE:AVTR) Price Target at $28.00

Avantor, Inc. (NYSE:AVTR) has received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $28.00.

A number of research firms have issued reports on AVTR. Robert W. Baird boosted their target price on shares of Avantor from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, July 29th. UBS Group decreased their price objective on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Morgan Stanley lifted their target price on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Finally, Evercore ISI cut their price objective on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd.

Avantor Trading Down 0.4 %

Shares of NYSE AVTR opened at $24.79 on Friday. Avantor has a 12-month low of $16.63 and a 12-month high of $28.00. The company has a market cap of $16.84 billion, a price-to-earnings ratio of 63.56, a price-to-earnings-growth ratio of 2.93 and a beta of 1.33. The company has a current ratio of 1.59, a quick ratio of 1.05 and a debt-to-equity ratio of 0.89. The stock’s 50 day simple moving average is $25.66 and its 200 day simple moving average is $24.34.

Avantor (NYSE:AVTR) last posted its earnings results on Friday, July 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. The company had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Avantor had a return on equity of 12.40% and a net margin of 5.28%. Equities research analysts expect that Avantor will post 1.01 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now owns 29,544 shares in the company, valued at approximately $740,372.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AVTR. Jennison Associates LLC boosted its position in shares of Avantor by 113.0% in the first quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock worth $63,857,000 after buying an additional 1,325,026 shares during the period. Swedbank AB acquired a new stake in Avantor during the 1st quarter worth about $2,707,000. Diversify Advisory Services LLC purchased a new position in Avantor during the 1st quarter valued at about $908,000. Leo Wealth LLC acquired a new position in shares of Avantor in the 4th quarter valued at about $906,000. Finally, Oliver Luxxe Assets LLC purchased a new stake in shares of Avantor in the first quarter worth approximately $1,538,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.